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THE UNIVERSITY OF TEXAS SYSTEM CANCER CENTER 
M. D. ANDERSON HOSPITAL AND TUMOR INSTITUTE Volume 28, Number 1 
Newsletter Becomes OncoLog 
by James M. Bowen, PhD, Vice MDAH that may be of interest and 
President for Academic Affairs 
This is the first issue of Oncolog, a 
report to all physicians regarding the 
status of cancer research and treat-
ment at The University of Texas Sys-
tem Cancer Center M. D. Anderson 
Hospital and Tumor Institute. For-
merly called the Newsletter and dis-
tributed bimonthly, Oncolog be-
comes, with this issue, a quarterly 
publication. 
rl°e·wsletter 
value to you. 
The UT Cancer Center was origi-
nally established to serve as a major 
referral hospital as well as a clinical 
and basic science research facility, 
with the fourfold mission of patient 
care, education, research, and pre-
vention. The Office of Academic Af-
fairs is responsible for the dissem-
ination of current and relevant infor-
mation that will aid the physician in 
As a publication of the UT Cancer 
Center, Oncolog has been redesigned to meet the needs of our 
readers more effectively. The educational value of the contents 
wi ll be emphasized to keep you informed of advances. in 
diagnosis and treatment methods at UT MDAH. Its mission will be 
to present the most recent developments in patient care, signifi-
cant diagnostic progress, and current clinical and basic science 
research activities. It will also serve to keep you informed about 
continuing cancer education conferences being held at UT 
the early detection of cancer and the 
follow-up treatment of cancer patients. Oncolog will continu-
ally strive to serve as a significant resource for the physician 
in maintaining current oncologic knowledge in professional prac-
tice. 
We encourage your active participation in Oncolog and invite 
you to suggest topics to be included in future issues. With your 
cooperation and assistance, Oncolog will achieve its goal of 
serving as an educational aid to you, the physician. 
Prolactinoma, a Prevalent Gonadoinhibitory 
Tumor, Responds Well to Treatment 
Prolactinoma, a benign, prolactin-producing pituitary tumor, is 
the most common tumor in the human body and occurs in 30% of 
the population. Since 1969, when human prolactin was first 
isolated~·· physicians at UT MDAH have successfully treated 
approximately 350 patients with prolactinoma, which can be a 
cause of sterility in both men and women. 
Prolactinoma produces excess prolactin in the body and has 
both an indirect and direct effect on the gonads, according to 
Naguib A. Samaan, MD, PhD, chief of the Section of Endocrinol-
ogy in the Department of Internal Medicine. The increased 
prolactin level indirectly affects the gonads by acting on the 
hypothalamus to prevent the pulsatile production of the luteiniz-
ing hormone releasing factor, while it directly inhibits formation of 
sperm and ova at the gonadal level and suppresses gonadal 
steroidogenesis. 
In women, the combination of these effects may cause 
infertility, menstrual irregularity, galactorrhea, reduction of vaginal 
secretions, or painful intercourse. Men may suffer infertility, 
impotency, or, in rare instances, galactorrhea or gynecomastia. In 
children, prolactinoma may inhibit normal growth and sexual 
development. In addition, individuals with large, invasive prolac-
tinomas, which destroy the pituitary tissue and bulge outside the 
pituitary fossa, may develop impaired lateral vision, brain com-
pression, headaches, rupture in the sphenoid sinus causing 
rhinorrhea, or other endocrine-related disorders. If a patient 
exhibits any of these symptoms or has a family history of pituitary 
tumors, hypercalcemia, and pancreatic tumors, the attending 
physician should suspect the presence of prolactinoma and refer 
the patient to an appropriate treatment center for diagnostic 
testing, particularly since some cases of prolactinoma may be 
familial or may be a component of Type 1 multiple endocrine 
neoplasia, according to Dr Samaan. 
A primary diagnostic tool to detect prolactinoma, used at UT 
MDAH and at other hospitals treating patients with the disease, is 
a radioimmunoassay that measures the level of serum prolactin, 
a test that Dr Samaan established soon after prolactin was 
isolated in humans. To obtain an accurate measurement of a 
patient's serum prolactin level, physicians at UT MDAH perform 
the test at least three times while the patient's serum prolactin is 
at basal level and then four additional times after injecting the 
patient with thyrotropic releasing hormone (TRH). Patients with 
Continued on page 2 
Prolactinoma. 
Continued from page 1 
prolactinoma have basal serum prolactin levels that are higher 
than normal and blunted serum prolactin responses after TRH 
stimulation. Because high prolactin levels may also be caused by 
oral contraceptives, analgesics, hypotensive agents, or hypothy-
roidism, standard procedure requires analysis of serum prolactin 
levels two months after patients cease taking d,rugs that may 
affect the level. Plasma estradiol in the women and testosterone 
in men are also measured, since they are usually suppressed in 
patients with prolactinoma. If the disease is suspected, sophis-
ticated x-ray methods are used to confirm the diagnosis. 
The two most common radiographic methods employed at UT 
MDAH to diagnose prolactinoma are computed axial tomography 
(CAT) and polytomography. These methods clearly delineate the 
pituitary gland and can reveal a tumor as well as suprasellar 
extension. The results of these procedures determine the appro-
priate treatment-either drug therapy or surgery-for each pa-
tient. 
If the prolactinoma is not visible on the polytomogram or CAT 
scan but the patient exhibits many of the symptoms of the 
disease, he or she may have hyperplasia of the prolactin-
producing cells or a prolactin-producing microadenoma, a small 
pituitary tumor 1 cm or less in diameter. Under these circum-
stances, the patient receives bromocriptine, a drug that inhibits 
prolactin secretion from the pituitary gland. Physicians at UT 
MDAH do not perform exploratory surgery to confirm the exist-
ence of a microadenoma; the risk of damaging the pituitary gland, 
though slight, is not worth the· potential benefits, according to Dr 
Samaan. 
Bromocriptine relieves the symptoms in 90% of the patients 
who receive it-those with hyperplasia or microadenomas not 
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demonstrable by x-ray, those not wishing to undergo surgery, and 
those not responding to surgery. Menstruation begins or returns 
in women, and fertility is restored in both men and women. 
Evidence indicates that bromocriptine may even shrink a pituitary 
tumor, although it is not a cure for prolactinoma; if the patient 
stops taking the drug, the prolactin level rises again . Although the 
drug does not cause any severe reactions in patients or 
congenital defects in children of women who take the drug, it may 
cause nausea, vomiting, diarrhea, or syncope, especially when 
first taken. Therefore, bromocriptine is administered in small, 
gradually increasing doses so that the patient may build up a 
tolerance to it. 
If the tumor is visible on the polytomogram or CAT scan and the 
patient is willing to undergo surgery, transphenoidal microdissec-
tion is performed, using the microscopic undervision dissection 
technique. This method enables the .surgeon , to . reach Ahe 
pituitary gland through an incision under the lip, into the gums, 
between the septum and the surrounding mucous membrane, 
through the sphenoid sinus, and into the floor of the pituitary 
fossa. Ordinarily, the tumor grows superficially from the anteroin-
ferior aspect of the pituitary gland and when removed leaves the 
normal pituitary tissue intact. 
After surgery, the patient usually recovers quickly and returns 
home on the fourth day. Four to 12 weeks later, most symptoms 
disappear and prolactin levels return to normal in 85% of the 
cases. Of the responding patients who desire to have children, 
85% to 90% do so without complication. In adolescent female 
patients whose sexual development was inhibited, menarche 
begins soon after surgery, and in both male and female adoles-
cents, secondary sexual characteristics appear. Those patients 
who do not respond to surgery, usually those with large invasive 
tumors, receive bromocriptine to inhibit high prolactin levels. Men 
and women beyond the reproductive age may receive adjuvant 
radiotherapy. 
Although physicians have been very successful in treating 
patients with prolactinoma, its cause remains a mystery, accord-
ing to Dr Samaan. Studies at UT MDAH have shown that 
symptoms often appear in women who have high estrogen levels, 
naturally occurring during pregnancy or produced exogenously 
byJ;,ir:tt:u :ont~oLi:1Ws~ 1.11 addlti.Qn, .tl;le.incisiAAge. .oJ ,t/:1.i .i:.Ji~e~e.j§ 
four times greater in women than in men. Although Dr Samaan 
does not directly implicate excess estrogen as a cause of 
prolactinoma, animal experiments have shown that estrogen can 
produce hyperplasia or a microadenoma from prolactin-pro-
ducing cells. In women, estrogen may unmask a preexisting 
asymptomatic prolactinoma or may stimulate development of 
potential tumor cells. 
While studies at UT MDAH may eventually lead to an under-
standing of the cause and prevention of the disease, Dr Samaan 
now focuses on treating individuals with prolactinoma. Based on 
postmortem studies, 25% of the population suffers from prolac-
tinoma without ever knowing they have the disease, he ex-
plained, adding that many of these individuals marry and · 
needlessly remain childless. 
(Physicians desiring additional information should write or call 
Naguib A. Samaan, MD, PhD, Department of Internal Medicine, 
MDAH Box 65, The University of Texas M. D. Anderson Hospital 
and Tumor Institute at Houston, 6723 Bertner Avenue, Houston, 
Texas 77030, (713) 792-2840.-ED) 
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Laboratory Research Continues to Advance 
Methods of Cancer Diagnosis and Therapy 
by James M. Bowen, PhD, Vice President for Academic Affairs 
In a recent presentation, Dr Bowen responded to questions 
about the future of cancer research. His examination of recent 
technology developed through basic science and its successful 
application to cancer diagnosis and treatment confirmed his 
optimism about that future. Here he summarizes the presenta-
tion. 
A friend who is a medical reporter recently asked me, "Don't 
you think it's true that cancer research has topped out? We've 
admittedly made a number of important accomplishments over 
the past 20 or 30 years, and now we're trying to apply those 
accomplishments as best we can, but we really don't have much 
to look forward to over the next 10 or 20 years." 
My competitive spirit was aroused, and I made a fairly detailed 
analysis of new technologies based on basic cancer research. I 
hope to convince you that cancer research is in a time of 
explosive advancement, producing new understandings and new 
technologic capabilities that will change the field forever. I could 
use many examples for this, but the ones I have chosen 
represent: (1) major advances in our understanding of biologic 
systems, (2) major advances in our ability to exploit these 
understandings with new or recently evolving technology, and (3) 
particular applications of basic research and their rapid transla-
tion into the patient care area. 
I want to begin with a brief description of the basis for a cancer 
cell's behavior. A fact that we take for granted, but which has 
particular significance in the context of understanding cancer, is 
that all the complex tissues and functioning systems that com-
prise the living body originate from a single cell. A sperm cell and 
an egg unite to produce an embryonic cell, and that original cell 
begins to divide, entering a period of tremendous proliferation. A 
series of highly ordered, highly regulated changes then begins to 
oc·cur in subsets of the cell population so that highly differentiated 
tissues arise. 
The important common denominator of differentiation is that all 
of the information needed to become any specialized cell in the 
body resides in every cell of the body. For that reason, an 
extremely complex and highly inclusive regulatory system must 
exist so that a kidney cell remains a kidney cell and so that if that 
kidney cell dies, it is replaced with a kidney cell and not a brain 
cell or a muscle cell. For every tissue there must be at least one 
gene for a substance that instructs those cells of that specific 
tissue to remain in place, to produce their products or carry out 
their specified function. When those cells divide to replace cells 
lost to aging or damage, the regulatory gene must control 
replacement with the appropriate kind of cell. An aberration in 
that regulatory activity can produce aberration in differentiation. 
One of the characteristics of the evolving differentiation se-
quence is that cells become less and less prone to grow and 
proliferate, less and less competitive with other cells in their 
environment, and more and more focused on their functional 
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activity. Kidney cells grow only to keep up with the body's growth 
or to replace lost kidney cells. Loss of either the functional aspect 
of the product of that regulatory gene or of the ability of that cell to 
respond to the signals from that regulatory gene tends to reverse 
the cell's progress on the path of differentiation, changing it to a 
more proliferative, more competitive, less functionally focused 
cell. When that functional backtracking reaches a certain level, 
the cell is no longer normal but rather possesses the behavioral 
characteristics we associate with disease, particularly with can-
cer. 
Now let me briefly review the background of cancer therapy. 
The original modality of cancer therapy was surgery. When it was 
discovered that tissues were susceptible to destruction by x-rays, 
gamma rays, and other sources of radiation and that rapidly 
proliferating tissues were more sensitive to radiation than normal 
tissues, radiotherapy became an important second modality. It 
extended the ability to kill tumor cells, allowed therapeutic 
measures to be taken in areas inaccessible to the surgeon, and 
helped us to control distant spread and metastasis. 
In the late 1940s and early 1950s, chemotherapy was added to 
the treatment choices. The basis for chemotherapy, like that of 
radiotherapy, is that the most rapidly proliferating cells are the 
most sensitive to cytotoxic substances, while normal, more 
differentiated, nonproliferative cells are more likely to survive. 
Also much like radiotherapy, chemotherapy extended the physi-
cian's ability to treat cancer that had spread or was too small or 
inaccessible for surgery. Many new drugs have proved effective, 
and many treatment advances have come from careful studies of 
the optimal combination of chemotherapy with surgery and radio-
therapy. 
Within the past 20 years, attention has also turned to manipula-
tion of the body's immunologic defenses against tumor cells. 
These early studies have suggested a fourth therapeutic modal-
ity, immunotherapy, which encompasses our attempts to under-
stand, exploit, and augment the body's own defenses. From 
there, we have enlarged our conceptual views to include a broad 
area that we term biologic response modification, defined as any 
therapeutic approach that augments any of the body's defenses 
against external encroachment or internal aberration. 
Let me emphasize that biologic response modification is 
complementary to surgery, radiotherapy, and chemotherapy. The 
initial tumor burden must be reduced by surgery, by radiotherapy, 
or by chemotherapy before biologic response modifiers can be 
used to control those last few tumor cells and to prevent 
recurrence of either that same tumor or another tumor. 
Interferons are the most remarkable biologic response mod-
ifiers we have studied. They represent the cell's own system for 
defending itself against the encroachment of a virus or other 
substance or agent that mimics foreign genetic material. Interfer-
on does not act on the cell in which it is made: Interferon is in fact 
a "messenger molecule" that leaves the cell in which it is induced 
and is taken up by a recipient cell. The recipient cell responds to 
Continued on page 6 
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Radiotherapy Plays Vital Role in Treatment 
Adjunctive radiotherapy for patients with malignant epithelial 
tumors of the parotid gland greatly reduces the risk of tumor 
recurrence after surgery, according to a recent retrospective 
study conducted at UT MDAH. The study also verified that the 
facial nerve, when not grossly involved, can be safely preserved 
with irradiation, even when its proximity to such a tumor might 
indicate otherwise. The study was conducted by Oscar M. 
Guillamondegui, MD, Department of Head and Neck Surgery, 
and Gilbert H. Fletcher, MD, Mary Jane Oswald, BS, David 
McNaney, MD, and Marsha D. McNeese, MD, all of the Depart-
ment of Radiotherapy. 
Adjunctive radiotherapy has been used systematically · at UT 
MDAH since the middle 1960s for selected patients with malig-
nant parotid tumors. Until recently, however, adequate evaluation 
of its controlling effect has been difficult, according to Dr 
Guillamondegui, because parotid tumors sometimes recur many 
years after initial treatment. Consequently, the precise role of 
irradiation for these patients has remained unclear, and no 
recommended treatment program has been widely accepted. 
Therefore, this study was undertaken to determine the overall 
benefit of adjunctive radiotherapy for patients with malignant 
epithelial tumors of the parotid gland and to clarify the clinical 
situations in which its use is effective. 
Records of 77 patients (35 males and 42 females between 10 
and 80 years of age) admitted to UT MDAH between 1954 and 
1977 with malignant epithelial parotid tumors were reviewed. All 
patients had been treated with surgery and adjunctive irradiation 
at the site of the parotid gland (5000-6000 rad, usually using the 
electron beam in combination with 60Co or 18-25 MeV photons) . 
Fifty-six patients had received additional irradiation (5000-6000 
Facial Nerve 
Temporal branches 
Parotid gland -----.~~~ c1\:-- --f:tt'~ 
and duct 
rad) to the cervical lymph nodes. The total number of local and 
regional recurrences were calculated; tumor recurrences were 
then related to histologic type and grade of disease, extent of 
residual disease, and extent of facial nerve resection. 
The results of the study indicated that adjunctive radiotherapy 
greatly reduces the recurrence rate of malignant parotid tumors: 
The overall control rate was 87%. Of the 77 patients, only six had 
recurrences in the primary site and four had recurrences in the 
cervical lymph nodes, yielding a local recurrence rate of 7.8% 
and a regional recurrence rate of 5.2%. (One patient had both 
local and regional recurrence and was included in both groups.) 
This local recurrence 'rate is at least four ' tirries less than •·Iocal '' 
recurrence rates reported for patients treated with surgery alone. 
No definite correlation between histologic type of tumor and 
tumor recurrence was found, although slightly more recurrences 
appeared in patients with adenocarcinomas. The different cell 
types and the number of local and regional recurrences of each 
were as follows: malignant mixed tumors, 1 local recurrence in 13 
patients; adenocarcinomas, 3 local and 2 regional recurrences in 
17 patients; low-grade mucoepidermoid carcinomas, O recur-
rences in 9 patients; high-grade mucoepidermoid carcinomas, 1 
local and 2 regional recurrences in 15 patients ; acinic cell 
carcinomas, O recurrences in 5 patients; adenocystic car-
cinomas, 1 local recurrence in 15 patients; unclassified tumors, O 
recurrences in 1 patient; and other types, 0 recurrences in 2 
patients. These findings indicate that the various histologic types 
of malignant epithelial parotid tumors are radiosensitive. 
A correlation between tumor radiosensitivity and histologic 
grade of tumor (high grade, low grade, or unknown) was 
determined based on the number of mitoses per high power field . 





For many patients with malignant 
tumors of the parotid gland, radio-
therapy as an adjunct to surgery both 
reduces the recurrence rate and ob-
viates facial paralysis through the 
preservation of the facial nerve. 
Anterior facial artery and vein 
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of Patients with Malignant Parotid Tumors 
Of the 77 patients included in the study, 63 had tumors of a 
histologically high grade, and all 10 local and regional recur-
rences developed in patients from this group. The low-grade 
mucoepidermoid and acinic cell carcinomas, which are noninva-
sive and slow-growing, did not recur. 
Adjunctive radiotherapy was also found to be effective in 
controlling limited residual disease, often present in or near the 
surgical margin or in nerve sheaths after excision of the parotid 
tumor mass. As support for this finding, the study showed no 
correlation between extent of residual disease and tumor recur-
rence, as follows: gross residual disease, 1 local and 1 regional 
recurrence in 14 patients; microscopic residual disease, 2 local 
and 1 regional recurrence in 26 patients; no residual disease, 3 
local and 2 regional recurrences in 33 patients; and unknown 
amount of residual disease, 0 recurrences in 4 patients. 
A most important finding, which again illustrates irradiation's 
control of residual disease, should settle the controversy sur-
rounding facial nerve preservation in these patients, a practice 
that often precludes total ablation of parotid tumor cells: Patients 
whose facial nerves had been preserved had no higher incidence 
of tumor recurrence. Thus, in most patients, possible or known 
residual disease on or near the nerve sheath had been controlled 
by irradiation. 
Preservation of this vital nerve, which runs through the parotid 
gland, has been a primary concern of physicians who treat 
patients with malignant parotid tumors, according to Dr Guil-
lamondegui. With complete resection of the facial nerve, which 
supplies motor fibers to all facial muscles, the patient suffers 
facial paralysis. Therefore, in many instances, the preferred 
treatment has been to preserve this nerve, if not grossly involved, 
and to control potential residual disease in the nerve area with 
irradiation. 
Confirming the benefit of this approach, the study related the 
extent of facial nerve resection to the number of local and 
regional recurrences, as follows: total facial nerve resection, 3 
local and 2 regional recurrences in 21 patients; partial facial 
nerve resection, 1 local and 1 regional recurrence in 21 patients; 
no facial nerve resection, 2 local and 1 regional recurrence in 35 
patients. 
Also of concern was whether the complications of adjunctive 
radiotherapy were too severe to warrant its application. Of the 
total patient population, only five, all of whom received adjunctive 
radiotherapy for extensive disease, suffered some long-term 
complications: osteonecrosis (two patients), soft-tissue necrosis 
(one patient), necrosis of the brain and temporomandibular joint 
(one patient), and myelitis (one patient). Three patients have 
been successfully treated for these complications; the patient 
with necrosis of the brain and the temporomandibular joint 
continues to suffer severe side effects; myelitis in another caused 
his death. These complications might have been minimized had 
the more advanced radiotherapy techniques used today been 
available. 
The study has confirmed that adjunctive radiotherapy is a vital 
Vol. 28, No. 1 
part of the treatment plan for selected patients with malignant 
parotid tumors: those with histologically high-grade tumors, 
locally invasive or metastatic disease, or gross or microscopic 
residual disease. The study has also established that, in selected 
patients, adjunctive radiotherapy allows the surgeon to preserve 
the facial nerve without increasing the risk of recurrence. 
(Physicians desiring additional information should write or call 
Oscar M. Guillamondegui, MD, Department of Head and Neck 
Surgery, MDAH Box 69, The University of Texas M. D. Anderson 
Hospital and Tumor Institute at Houston, 6723 Bertner Avenue, 
Houston, Texas 77030, (713) 792-6920.-ED) 
The University of Texas 
M. D. Anderson Hospital and Tumor Institute 
at Houston 
DEPARTMENT OF PEDIATRICS 
8th Mental Health Conference 
Life, Faith, 
Hope, and Magic 
The Chaplaincy in a Children's 
Cancer Center 
April 21-22, 1983 
Shamrock Hilton Hotel 
Houston, Texas 
Cochairpersons: Jan van Eys, MD, PhD, Department of 
Pediatrics, and Edward J. Mahnke, DD, Department of 
Chaplaincy and Pastoral Education 
Interviews with parents and children during and after the 
experience with cancer indicate that religion is a primary 
source of support. Therefore, this conference will focus on 
the role of clergy members as an integral part of the health 
care team. 
For registration information, write or call the Office of 
Conference Services, HMB Box 131 , The University of 
Texas M. D. Anderson Hospital and Tumor Institute at 




Continued from page 3 
the message by synthesizing a secondary protein that confers 
resistance. 
We have identified two key areas of antiviral interferon activity. 
The so-called antiviral proteins, or inhibitory proteins, are pro-
duced against early stages of virus replication. These stages are 
so early that they are common to most viruses, which allows for a 
broad spectrum of interferon-induced resistance. For example, if 
interferon production is induced in the cell by influenza virus, that 
cell is not only resistant to influenza virus but to virtually every 
other virus. 
Perhaps more important from the standpoint of cancer therapy 
is the fact that interferons not only recognize foreign genes and 
induce resistance in recipient cells, they also recognize aberrant 
genetic behavior patterns in uninfected cells. Thus, they act 
against the proliferative uncontrolled growth phases in cells such 
as some cancer cells. 
Interferons inhibit the growth of cells in tissue culture. They 
inhibit the same tumor cells in a susceptible animal that they 
inhibit in culture. They may also inhibit normal cells that are in 
highly proliferative states, such as cells of the blood-forming 
tissues, cells of the gastric and colonic mucosa, hair-producing 
cells, and so on. But interferons are more effective inhibitors of 
tumor cells than of normal cells because the proliferation rates of 
tumor cells are often much higher than those of even the most 
rapidly proliferating normal cells in the body. 
Interferons are also immunomodulators. They inhibit both the 
proliferation and function of some kinds of immune cells and 
enhance the proliferation and function of others. (Figure 1 
summarizes these activities of interferon.) The immunomodula-
6 
Figure 1 
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(sensitized cyotoxic lymphocytes) 
(natural killer cells) 
tory property is a two-edged sword , however, since large 
quantities of interferons may produce immune compromise. 
Nevertheless, the interferons are extremely important biologic 
response modifiers, which have already shown therapeutic 
benefits for breast cancer, melanoma, multiple myeloma, and a 
variety of other tumors. 
One problem exists with interferon, however-it is species 
specific. In the early 1960s, drug companies committed millions 
of dollars to the production of kilogram quantities of chick 
interferon. It turned out, however, that a kilogram of chick 
interferon is a useful therapeutic agent only if you happen to be 
treating a sick chicken. 
If we are to treat human disease with interferon we must have 
human interferon. The first clinical trial of interferon exemplifies 
this problem's significance: In Scandinavia about 16 years ago, 
18 young patients with osteosarcoma were treated with interfer-
on. To treat those 18 patients, all the interferon made from every 
blood donation in the entire country of Finland for one full year 
was needed. 
It is thus very clear that if interferon is ever to be fully exploited 
as a chemotherapeutic agent and for its other potentials, we must 
have a larger source. How are we going to get human interferon if 
we don't have human cells? Basic science has placed the answer 
to that question in our hands through recombinant DNA technol-
ogy. This technology is a beautiful example of the impact of basic 
research on therapy for cancer and other diseases because it 
was first developed as a solution to simple academic laboratory 
problems with no visible relevance to the treatment of cancer or 
any other disease. 
In the course of their research, two scientists at Stanford 
University discovered that restriction endonucleases were able to 
break DNA molecules from any organism at specific points. 
These pieces could then be recombined with DNA pieces from 
any other organism, in any order. Since that discovery in 1973, 
many more restriction endonucleases have been discovered, 
each cutting DNA molecules at specific sites. Those pieces, too, 
could be recombined in any order from any organism. By 
inserting the resulting manufactured genes into an appropriate 
organism, the products of any added foreign genes can be 
expressed. (Figure 2 summarizes some of the biologic products 
available through recombinant DNA technology.) 
Escherichia coli is the organism most often used as the 
recipient of foreign genes. It is a simple microorganism that is 
easy and inexpensive to culture, and it has genes that are always 
read in the same sequence-these genes are expressed abso-
lutely predictably. When they mutate, the genes can be identified. 
More important, the microorganism will express any gene, no 
matter what its source, if it is inserted into its genome. 
Thus, once the first human interferon gene was identified, it 
became a simple matter to apply recombinant DNA technology to 
splice that human gene onto the end of the bacterial chromo-
some. That bacterium then synthesized large quantities of human 
interferon. The first clinical trial of human interferon produced by 
recombinant DNA technology is under way right now. In most 
respects this interferon appears to be as good as human 
interferon produced by human cells. 
Another area that has revolutionized an entire field of endeavor 
is hybridoma technology. A quick tour of immunology will make its 
significance clear: Although there are many different functional 
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Figure 2 
RECOMBINANT DNA TECHNOLOGY 
IN CANCER RESEARCH 
SYNTHESIS OF BIOLOGICALLY ACTIVE AGENTS 
• Interferons 
• Hormones 
• "Tailored" antibiotics and other drugs 
SYNTHESIS AND STUDY OF GENE PRODUCTS 
ASSOCIATED WITH THE MALIGNANT PROCESS 
• Differentiation factors 
• Phosphokinases 
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populations of immune cells in our bodies and in the bodies of all 
complex living things, they fall into two basic populations-those 
that produce antibodies (8 cells) and those that directly interact 
with the target substance or target cell (T cells). 
B cells have a remarkable set of properties. They contain within 
thei r own genetic makeup a programmabil ity that puts to shame 
the finest computer ever devised by man. They are able to 
recognize an antigen, and realizing their own interactive capabil-
ity, they produce antibodies absolutely specific for the antigen. 
The B cell is thus programmed, as are all generations of its 
daughter cells, to produce that antibody and that antibody only. A 
subpopulation of those programmed cells does stop making the 
antibody, but it retains the ability to produce that antibody 
whenever the body is exposed to the same antigen again. 
These B cells, which reside in the spleen of highly evolved 
organisms, die very rapidly, usually within a few hours, if they are 
removed from the spleen. Thus, they have extremely limited 
growth potential. Like other cells of the body, B cells can undergo 
malignant change. The most important B cell cancer is multiple 
myeloma, which is sometimes known as cancer of the bone 
mauow because the malignant change occurs when the B cells 
are undergoing initial development in the bone marrow. 
Myeloma cells have an interesting set of properties that 
contrast with those of their normal counterparts. If myeloma cells 
are removed from the body, and if they are given the appropriate 
nutrients, they can grow indefinitely, having lost the senescence 
mechanism of the normal B cell. In addition, their growth is 
unrestrained. They produce antibody protein , but in an unpro-
grammed form, and they produce it in quantities a hundred times 
greater than does the normal spleen cell. They are also able to 
grow in an appropriate animal. For example, mouse myeloma 
cells can be transplanted to a mouse of the same genetic 
configuration, and a new myeloma tumor will form and will keep 
on growing, ultimately killing the mouse. In addition, the cells lose 
the programmability of the normal cell, one of the characteristics 
of cancer cells in general. While the normally differentiated cell is 
focused on function, not growth, the cancer cell is focused on 
unrestrained growth. 
Dr Cesar Milstein, a scientist in Great Britain, asked himself a 
very academic question: "What would happen if I fused a normal 
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spleen cell with a multiple myeloma cell?" What happened when 
he did turned the field of immunology upside down. From his 
fusing of a normal antibody-producing spleen cell and a multiple 
myeloma cell , a hybridoma resulted (Figure 3). From the mye-
loma cell , the hybridoma obtained an indefinite life span, the 
ability to grow unrestrained both in tissue culture and in a suitable 
animal, and continuous immunoglobulin production capability. 
From the normal spleen cell, it obtained specific programmability. 
What resulted was a cellular factory that could forever produce a 
specific antibody in large quantities. If a clone is produced from a 
single hybrid cell, the programmability of a single B cell is 
available in large quantities. The resulting monoclonal antibody 
has absolute specificity. 
All of the uses of this hybridoma technology for cancer therapy 
depend on one of the manifestations of the difference between 
cancer cells and normal cells-the expression of new chemical 
signals on the surface, recognizable by the immune system. It is 
possible to make monoclonal antibodies against a variety of 
these signal substances-say, a marker specific for ovarian 
cancer. The monoclonal antibody will not react with anything in 
the body except an ovarian cancer cell. It becomes an absolutely 
specific reagent for the diagnosis of ovarian cancer cells. 
Monoclonal antibodies complexed to plastic spheres can be 
used to select a specific antigen from a mixture of a thousand 
different antigens. We can complex antibodies to a variety of 
substances, dyes, radioactive atoms, and even large complex 
substances such as drugs, and they do not lose their specificity. 
For example, suppose a patient has an ovarian tumor. If a drug 
that is potent against ovarian cancer is complexed to a mono-
clonal antibody specific for ovarian cancer, the drug can be 
delivered through the blood stream to the ovarian tumor and 




• Indefinite life span 
• Unrestrained growth 
• Continuous immunoglobu-
lin production 




NORMAL SPLEEN CELLS 
• Short extracorporeal life 
span 
• Limited growth 
• Programmable for mono-
specific antibody 
• Specificity retention for life 
HYBRIDOMA 
• Indefinite life span 
• Growth in vitro and in vivo 
• Continuous immunoglobulin production 
• Specific, monoclonal antibody 
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Continued from page 7 
nowhere else. Suppose the tumor has already metastasized to 
the liver, but the few hundred cells are undetectable. The 
monoclonal antibody doesn't care. It will deliver the cytotoxic drug 
to those few hundred cells hidden In the liver. 
Another use for monoclonal antibodies Is In the programming 
of killer T cells. Although there are a variety of ways these 
lymphocytes are directed, the most significant Is by adsorption 
to antibodies produced against a given substance; the unpro• 
grammed killer cells then become specific killer cells for whatever 
cell Is carrying the specific antigen. tf a few hundred molecules of 
a specific antlovarlan tumor antibody produced by monoclonal 
techniques are attached to a patient's lymphocytes and those 
lymphocytes are returned to the patient, the killer T cells are no 
longer unprogrammed. They are T cells programmed to attack 
and destroy the ovarian tumor. 
In certain kinds of systemic cancers, particularly those of the 
blood system, fairly large amounts of monoclonal anl.ibody alone 
may destroy the tumor. Or Evan Hersh and his colleagues In our 
Department of Cllnlcal Immunology have Just completed a small, 
limited protocol us ng monoclonal antibodies produced galnst a 
marker spec! te for a partk:\Jlar k nd ol human I u em a. In some 
patients, the skin reactivity ol th s leukem a completely disap-
peared after two or three courses ol therapy. 
I witl now bring th s discussion full circle and ask you the 
question that I was asked. With these advances n mind, has 
cancer research realty topped out? Is there nothing to look 
forward to In cancer research over the neX1 few years? The news 
of cancer research's death Is greatly exaggerated, seriously 
mistaken, and shortsighted. Not only does it live, but new 
technology to exploit new knowledge has never been as promis-
ing. I believe new technologies will continue to change our entire 
view of the management of cancer and diseases like cancer 
within this century. The three kinds of cancer that produce 50% of 
all cancer deaths have been most resistant to all therapies that 
are now available-cancers of the lung, breast, and colon. 
However, new technologies are now being applied to these 
areas, particularly colon and lung cancers. We will begin to see 
our first truly sucoessful inroads into the management of even 
these most refractory cancers in the neX1 five to ten years. 
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27th Annual Clinical Conference 
New Perspectives in 
Human Lymphoma 
Presented by 
The University of Texas 
M. D. Anderson Hospital and 
Tumor Institute 
at Houston 
November 9·12, 1983 
Shamrock Hilton Hotel 
Houston, Texas 
For ddltlonal Information, write or call the Office of 
Conference Services, HMB Box 131 . The Unlvers ty ol 
Texas M. O. Anderson Hospital and Tumor Institute at 
Houston, 6723 Bertner Avenue, Houston. Texas 77030. 
(713) 792-2222. 
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